MembershipCustomer ServiceTools & FeaturesAdsMoreDow Jones Products
No matching tags
No matching tags
No matching tags
No matching tags
No matching tags
No matching tags
Donanemab slowed cognitive and functional decline of patients with mild Alzheimer?s by 32% compared with placebo
As said here by Jonathan D. Rockoff